| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.997 | 0.001 | 0.997 | Alpha 2a adrenoreceptor antagonist | 0.946 0.002 DBMET02090 | ||
| 0.996 | 0.001 | 0.996 | Alpha 2 adrenoreceptor antagonist | 0.902 0.002 DBMET02090 | ||
| 0.996 | 0.001 | 0.996 | Alpha 2b adrenoreceptor antagonist | 0.898 0.002 DBMET02090 | ||
| 0.996 | 0.001 | 0.996 | 5 Hydroxytryptamine 2B antagonist | 0.995 0.001 DBMET02090 | ||
| 0.996 | 0.001 | 0.996 | Dopamine D1 antagonist | 0.747 0.002 DBMET02090 | ||
| 0.996 | 0.001 | 0.996 | Alpha 2c adrenoreceptor antagonist | 0.857 0.002 DBMET02090 | ||
| 0.996 | 0.001 | 0.996 | Dopamine D2 agonist | 0.988 0.002 DBMET02090 | ||
| 0.995 | 0.001 | 0.995 | Alpha adrenoreceptor antagonist | 0.989 0.002 DBMET02090 | ||
| 0.996 | 0.002 | 0.996 | 5 Hydroxytryptamine antagonist | 0.964 0.002 DBMET02090 | ||
| 0.995 | 0.001 | 0.995 | Dopamine agonist | 0.981 0.002 DBMET02090 | ||
| 0.995 | 0.001 | 0.995 | 5 Hydroxytryptamine 2 antagonist | 0.971 0.002 DBMET02090 | ||
| 0.993 | 0.001 | 0.993 | 5 Hydroxytryptamine 2C antagonist | 0.778 0.003 DBMET02090 | ||
| 0.992 | 0.001 | 0.992 | 5 Hydroxytryptamine 1B antagonist | 0.623 0.003 DBMET02090 | ||
| 0.99 | 0.002 | 0.99 | Dopamine D2 antagonist | 0.736 0.004 DBMET02090 | ||
| 0.987 | 0.002 | 0.987 | Dopamine antagonist | 0.706 0.004 DBMET02090 | ||
| 0.983 | 0.002 | 0.983 | 5 Hydroxytryptamine 1 antagonist | 0.796 0.003 DBMET02090 | ||
| 0.982 | 0.001 | 0.982 | Alpha 1a adrenoreceptor antagonist | 0.8 0.003 DBMET02090 | ||
| 0.982 | 0.002 | 0.982 | Antiadrenergic | 0.957 0.003 DBMET02090 | ||
| 0.982 | 0.002 | 0.982 | Adrenaline antagonist | 0.956 0.003 DBMET02090 | ||
| 0.979 | 0.002 | 0.979 | Spasmolytic | 0.836 0.004 DBMET02090 | ||
| 0.977 | 0.002 | 0.977 | Alpha 1 adrenoreceptor antagonist | 0.783 0.003 DBMET02090 | ||
| 0.972 | 0 | 0.972 | Prolactin release inhibitor | 0.896 0 DBMET02090 | ||
| 0.967 | 0.002 | 0.967 | 5 Hydroxytryptamine 1A antagonist | 0.72 0.003 DBMET02090 | ||
| 0.966 | 0.002 | 0.966 | 5 Hydroxytryptamine 2A antagonist | 0.637 0.004 DBMET02090 | ||
| 0.95 | 0.001 | 0.95 | Alpha 1d adrenoreceptor antagonist | 0.713 0.003 DBMET02090 | ||
| 0.944 | 0.001 | 0.956 | 5 Hydroxytryptamine 1B agonist | 0.956 0.001 DBMET02090 | DBMET02090 | |
| 0.943 | 0 | 0.943 | Prolactin inhibitor | 0.744 0 DBMET02090 | ||
| 0.924 | 0.002 | 0.924 | 5 Hydroxytryptamine 7 antagonist | 0.835 0.003 DBMET02090 | ||
| 0.914 | 0.002 | 0.914 | Alpha adrenoreceptor agonist | 0.303 0.005 DBMET02090 | ||
| 0.914 | 0.003 | 0.914 | 5 Hydroxytryptamine agonist | 0.865 0.003 DBMET02090 | ||
| 0.906 | 0.002 | 0.906 | Dopamine D5 antagonist | 0.789 0.002 DBMET02090 | ||
| 0.892 | 0.002 | 0.892 | Alpha 1b adrenoreceptor antagonist | 0.514 0.004 DBMET02090 | ||
| 0.884 | 0.001 | 0.884 | 5 Hydroxytryptamine 2 agonist | 0.266 0.004 DBMET02090 | ||
| 0.877 | 0.002 | 0.877 | P-glycoprotein inhibitor | 0.817 0.003 DBMET02090 | ||
| 0.863 | 0.004 | 0.863 | Nootropic | 0.795 0.005 DBMET02090 | ||
| 0.861 | 0.002 | 0.861 | Cholinergic antagonist | 0.568 0.004 DBMET02090 | ||
| 0.859 | 0.002 | 0.859 | Acetylcholine antagonist | 0.561 0.004 DBMET02090 | ||
| 0.854 | 0.002 | 0.854 | 5 Hydroxytryptamine 1F antagonist | 0.812 0.003 DBMET02090 | ||
| 0.851 | 0.005 | 0.851 | Analgesic | 0.806 0.005 DBMET02090 | ||
| 0.846 | 0.003 | 0.846 | 5 Hydroxytryptamine 1 agonist | 0.833 0.003 DBMET02090 | ||
| 0.797 | 0.002 | 0.797 | 5 Hydroxytryptamine 2A agonist | 0.185 0.004 DBMET02090 | ||
| 0.773 | 0.002 | 0.773 | Cyclic AMP phosphodiesterase inhibitor | 0.602 0.004 DBMET02090 | ||
| 0.754 | 0.005 | 0.754 | Thioredoxin glutathione reductase inhibitor | 0.611 0.014 DBMET02090 | ||
| 0.706 | 0.004 | 0.706 | Hypoxia-inducible factor 1 alpha inhibitor | 0.374 0.037 DBMET02090 | ||
| 0.699 | 0.002 | 0.699 | Dopamine D3 agonist | 0.373 0.003 DBMET02090 | ||
| 0.689 | 0.003 | 0.689 | Dopamine D3 antagonist | 0.134 0.018 DBMET02090 | ||
| 0.626 | 0.005 | 0.626 | Vasodilator | 0.624 0.005 DBMET02090 | ||
| 0.611 | 0.003 | 0.611 | 5 Hydroxytryptamine 1D antagonist | 0.218 0.006 DBMET02090 | ||
| 0.586 | 0.003 | 0.586 | Acetylcholine M1 receptor antagonist | 0.307 0.013 DBMET02090 | ||
| 0.567 | 0.003 | 0.567 | 5 Hydroxytryptamine 5A antagonist | 0.177 0.005 DBMET02090 | ||
| 0.542 | 0.003 | 0.542 | 5 Hydroxytryptamine 5 antagonist | 0.167 0.006 DBMET02090 | ||
| 0.537 | 0.001 | 0.537 | 5 Hydroxytryptamine 4 antagonist | 0.282 0.002 DBMET02090 | ||
| 0.534 | 0.004 | 0.534 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.451 0.006 DBMET02090 | ||
| 0.518 | 0.004 | 0.518 | Dopamine D4 antagonist | 0.076 0.034 DBMET02090 | ||
| 0.508 | 0.001 | 0.648 | 5 Hydroxytryptamine 1D agonist | 0.648 0.001 DBMET02090 | DBMET02090 | |
| 0.505 | 0.004 | 0.505 | Opioid mu receptor antagonist | 0.335 0.005 DBMET02090 | ||
| 0.492 | 0.004 | 0.492 | Opioid antagonist | 0.314 0.005 DBMET02090 | ||
| 0.47 | 0.003 | 0.47 | 5 Hydroxytryptamine 2C agonist | 0.276 0.004 DBMET02090 | ||
| 0.497 | 0.038 | 0.497 | Antiobesity | |||
| 0.405 | 0.002 | 0.405 | 5 Hydroxytryptamine 6 antagonist | 0.132 0.008 DBMET02090 | ||
| 0.402 | 0.002 | 0.402 | Dopamine D1 agonist | 0.247 0.002 DBMET02090 | ||
| 0.36 | 0.004 | 0.36 | Alpha 1 adrenoreceptor agonist | 0.076 0.025 DBMET02090 | ||
| 0.316 | 0.008 | 0.316 | Acetylcholine muscarinic antagonist | 0.139 0.051 DBMET02090 | ||
| 0.388 | 0.098 | 0.388 | Cyclophilin D inhibitor | |||
| 0.269 | 0.006 | 0.269 | 5 Hydroxytryptamine 1A agonist | 0.108 0.014 DBMET02090 | ||
| 0.259 | 0.009 | 0.259 | Androgen antagonist | |||
| 0.242 | 0.004 | 0.242 | Alpha 2 adrenoreceptor agonist | 0.105 0.013 DBMET02090 | ||
| 0.225 | 0.005 | 0.225 | Adrenaline agonist | |||
| 0.167 | 0.005 | 0.167 | Beta 3 adrenoreceptor antagonist | 0.073 0.03 DBMET02090 | ||
| 0.193 | 0.038 | 0.193 | Catenin beta inhibitor | 0.173 0.061 DBMET02090 | ||
| 0.161 | 0.014 | 0.161 | 5 Hydroxytryptamine uptake inhibitor | 0.096 0.027 DBMET02090 | ||
| 0.19 | 0.045 | 0.19 | NOS3 expression enhancer | 0.166 0.059 DBMET02090 | ||
| 0.126 | 0.002 | 0.126 | 5 Hydroxytryptamine 6 agonist | 0.053 0.004 DBMET02090 | ||
| 0.133 | 0.042 | 0.133 | Nav1.4 sodium channel blocker | 0.119 0.053 DBMET02090 | ||
| 0.117 | 0.027 | 0.117 | Alpha 2d adrenoreceptor antagonist | 0.113 0.03 DBMET02090 | ||
| 0.113 | 0.027 | 0.113 | Opioid kappa receptor antagonist | 0.087 0.048 DBMET02090 | ||
| 0.099 | 0.025 | 0.099 | Neuronal nicotinic receptor antagonist | |||
| 0.107 | 0.035 | 0.107 | Acetylcholine nicotinic antagonist | |||
| 0.083 | 0.025 | 0.083 | Beta adrenoreceptor antagonist | |||
| 0.069 | 0.012 | 0.069 | Somatostatin 1 antagonist | 0.063 0.014 DBMET02090 | ||
| 0.067 | 0.01 | 0.067 | Nicotinic receptor beta4 subunit antagonist | 0.057 0.013 DBMET02090 | ||
| 0.093 | 0.039 | 0.093 | Somatostatin 1 agonist | 0.076 0.055 DBMET02090 | ||
| 0.069 | 0.017 | 0.069 | Nicotinic receptor alpha4 subunit antagonist | 0.06 0.022 DBMET02090 | ||
| 0.121 | 0.07 | 0.121 | M18 aspartyl aminopeptidase inhibitor | 0.108 0.082 DBMET02090 | ||
| 0.058 | 0.013 | 0.058 | Somatostatin 2 antagonist | 0.049 0.015 DBMET02090 | ||
| 0.133 | 0.091 | 0.133 | Hemostatic | |||
| 0.068 | 0.028 | 0.068 | Beta 1 adrenoreceptor antagonist | |||
| 0.171 | 0.139 | 0.171 | Immunostimulant | |||
| 0.152 | 0.126 | 0.152 | Platelet aggregation inhibitor | |||
| 0.057 | 0.032 | 0.057 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.038 | 0.022 | 0.038 | p53 inhibitor | 0.034 0.026 DBMET02090 | ||
| 0.036 | 0.023 | 0.036 | Somatostatin 5 agonist | |||
| 0.108 | 0.095 | 0.108 | Lck kinase inhibitor | |||
| 0.058 | 0.048 | 0.058 | Opioid delta receptor antagonist | |||
| 0.203 | 0.194 | 0.203 | Immunosuppressant | |||
| 0.031 | 0.022 | 0.031 | Somatostatin agonist | |||
| 0.077 | 0.069 | 0.077 | Antineoplastic alkaloid | |||
| 0.03 | 0.023 | 0.03 | Somatostatin 5 antagonist | |||
| 0.015 | 0.009 | 0.015 | Somatostatin 2 agonist | |||
| 0.042 | 0.038 | 0.042 | Opioid mu receptor agonist | |||
| 0.041 | 0.064 | 0.056 | Protein kinase C eta inhibitor | 0.056 0.037 DBMET02090 | DBMET02090 | |
| 0.021 | 0.049 | 0.034 | 1,3-Beta-glucan synthase inhibitor | 0.034 0.008 DBMET02090 | DBMET02090 | |
| 0.037 | 0.105 | 0.095 | Antineoplastic antibiotic | 0.095 0.049 DBMET02090 | DBMET02090 | |
| 0.149 | 0.24 | 0.225 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.225 0.13 DBMET02090 | DBMET02090 | |
| 0.044 | 0.145 | 0.087 | Kallikrein 7 inhibitor | 0.087 0.009 DBMET02090 | DBMET02090 | |
| 0.052 | 0.153 | 0.085 | Protein kinase C mu inhibitor | 0.085 0.074 DBMET02090 | DBMET02090 | |
| 0.046 | 0.17 | 0.21 | Chymotrypsin inhibitor | 0.21 0.008 DBMET02090 | DBMET02090 | |
| 0.03 | 0.169 | 0.104 | Elastase 1 inhibitor | 0.104 0.018 DBMET02090 | DBMET02090 | |
| 0.01 | 0.385 | 0.069 | Plasminogen activator inhibitor | 0.069 0.033 DBMET02090 | DBMET02090 | |
| 0.009 | 0.461 | 0.064 | Elastase inhibitor | 0.064 0.027 DBMET02090 | DBMET02090 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |